U.S. Markets closed

Endo International plc (ENDP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.3677-0.0223 (-5.72%)
At close: 04:00PM EDT
0.3628 -0.00 (-1.33%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.3900
Bid0.3707 x 2200
Ask0.3747 x 2200
Day's Range0.3677 - 0.3967
52 Week Range0.2800 - 7.0700
Avg. Volume15,298,220
Market Cap85.921M
Beta (5Y Monthly)1.05
PE Ratio (TTM)1.26
EPS (TTM)0.2920
Earnings DateFeb 23, 2022 - Feb 28, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.33
  • Zacks

    Endo (ENDP) Inks Deal for Osteoarthritis Knee Pain Drug

    Endo (ENDP) collaborates with Taiwan Liposome to commercialize TLC599, an extended and controlled release liposomal formulated dexamethasone for chronic knee osteoarthritis (OA) pain.

  • Benzinga

    Endo Inks US Pact For Osteoarthritis Pain Injectable

    TLC BioSciences has entered a commercialization agreement with Endo International plc (NASDAQ: ENDP) for the U.S. rights of TLC599, a proprietary BioSeizer sustained-release injectable in Phase 3 development for osteoarthritis pain. Under the agreement signed with Endo's subsidiary Endo Ventures Limited (EVL), TLC will primarily be responsible for developing the product, and EVL for obtaining regulatory approval and commercialization of the product in the U.S. TLC will receive an upfront payment

  • PR Newswire

    Endo Executes Agreement With TLC to Commercialize Phase 3 Orthopedic Product for the Treatment of Osteoarthritis Knee Pain

    Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited (EVL) has executed an agreement with Taiwan Liposome Company, Ltd. (TLC), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, to commercialize TLC599, a TLC investigational product. TLC599 is an injectable compound in Phase 3 development for the treatment of osteoarthritis knee pain.